Boosting a characteristic cell cycle could bring down ventilator-related lung damage

Overview

• Post By : Kumar Jeetendra


• Source: Ohio State University


• Date: 12 Jan,2021

An unfortunate truth about the use of mechanical ventilation to save the lives of patients in respiratory distress is that the pressure used to inflate the lungs is very likely to cause further lung damage.

In a new study, scientists identified a molecule that’s produced by immune cells during mechanical ventilation to try to decrease inflammation, but isn’t able to completely prevent ventilator-induced injury to the lungs.

The group is working on exploiting that natural process in pursuit of a therapy that could lower the chances for lung damage in patients on ventilators. Delivering high levels of the valuable molecule using a nanoparticle was capable of fending off ventilator-related lung damage in mice on mechanical ventilation.

Our data suggest that the lungs know they’re not supposed to be overinflated in this way, and the immune system does its best to try to fix it, but unfortunately it’s not enough. How can we exploit this response and take what nature has done and augment that? That led to the therapeutic aims in this study.”

Dr. Joshua A. Englert, Study Co-lead Author, Assistant Professor, Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Wexner Medical Center

The work builds upon findings in the lab of co-lead writer Samir Ghadiali, professor and chair of biomedical engineering at Ohio State, who for decades has studied how the physical force generated during mechanical ventilation activates inflammatory signaling and causes lung injury.

Efforts in other labs to engineer venting systems that could reduce harm to the lungs haven’t panned out, Ghadiali said.

“We haven’t found ways to ventilate patients in a clinical setting that completely eliminates the injurious mechanical forces,” he said. “The alternative is to use a drug that reduces the injury and inflammation due to mechanical stresses.”

The research is published today (Jan. 12, 2021) in Nature Communications.

Though a treatment for humans is years away, the progress comes at a time when more patients than ever before are requiring mechanical ventilation: Cases of acute respiratory distress syndrome (ARDS) have skyrocketed because of the continuing COVID-19 pandemic. ARDS is among the most common causes of respiratory failure that leads to putting patients on a ventilator.

“Before COVID, there were a few hundred thousand cases of ARDS in the USA each year, the majority of which required mechanical ventilation. But in the past year there have been 21 million COVID-19 patients in danger,” said Englert, a physician who treats ICU patients.

The immune response to venting as well as the inflammation that comes with it may add to fluid build-up and low oxygen levels in the lungs of patients so sick that they require life support.

The molecule that lessens inflammation in response to mechanical ventilation is called microRNA-146a (miR-146a). MicroRNAs are small segments of RNA that inhibit genes’ protein-building works – in this case, turning off the production of proteins that promote inflammation.

The researchers found that immune cells in the lungs called alveolar macrophages – whose job is to protect the lungs from infection – activate miR-146a when they are subjected to pressure that mimics mechanical ventilation. This action makes miR-146a part of the inherent, or immediate, immune reaction launched from the body to begin its fight against what it is perceiving as an infection – the mechanical ventilation.

“This means an inherent regulator of the immune system is activated by mechanical stress. That makes me think it is there for a reason,” Ghadiali said. That reason, he said, is to help calm the inflammatory nature of this very immune response that’s producing the microRNA.

The research team confirmed the moderate increase of miR-146a levels in alveolar macrophages in a series of tests on cells from donor lungs that were subjected to mechanical strain and in mice on tiny ventilators. The lungs of genetically modified mice that lacked the microRNA were more heavily damaged by ventilation than lungs in normal mice – pointing to miR-146a’s protective role in lungs through mechanical breathing assistance. Finally, the researchers analyzed cells from lung fluid of ICU patients on ventilators and discovered miR-146a levels in their immune cells have been increased also.

The problem: The expression of miR-146a under ordinary circumstances isn’t high enough to stop lung damage from prolonged ventilation.

The planned therapy would be introducing higher levels of miR-146a directly to the lungs to ward off inflammation that can result in injury. When overexpression of miR-146a was prompted in cells which were then subjected to mechanical stress, inflammation was reduced.

To check the treatment in mice on ventilators, the team delivered nanoparticles containing miR-146a directly to mouse lungs – which resulted in a 10,000-fold increase in the molecule that reduced inflammation and retained oxygen levels normal. In the lungs of ventilated mice that received”placebo” nanoparticles, the rise in miR-146a was modest and offered little protection.

From here, the team is testing the effects of manipulating miR-146a levels in other cell types – these functions can differ dramatically, depending on each cell type’s job.

“In my mind, the next step is demonstrating how to utilize this technology as a precision tool to target the cells that need it the most,” Ghadiali stated.